Voriconazole, a second-generation triazole, has recently been appro ved by t he Food and Drug Administration (FDA) to treat invasive aspergillosis and refrac tory infections with Scedosporium apiospermum or Fusarium s...Voriconazole, a second-generation triazole, has recently been appro ved by t he Food and Drug Administration (FDA) to treat invasive aspergillosis and refrac tory infections with Scedosporium apiospermum or Fusarium spp. The reported side -effects of voriconazole include visual changes, headaches, elevated hepatic e nzymes, Steven-Johnson syndrome, toxic epidermal necrolysis, chelitis, photose nsitivity, discoid lupus erythematosus and anaphylactoid infusion reactions. Pse udoporphyria was first described in association with nalidixic acid. It has the same clinical and histologic features as porphyria cutanea tarda (PCT) but is di stinguished by normal porphyrin levels in the serum, urine and stool. We present the case of a patient who developed pseudoporphyria after receiving treatment w ith voriconazole.展开更多
Pyoderma gangrenosum (PG) is an uncommon cutaneous disease of unknown etiology. In 50 percent of affected patients, PG is associated with systemic disease including inflammatory bowel disease, arthritis, and hematolog...Pyoderma gangrenosum (PG) is an uncommon cutaneous disease of unknown etiology. In 50 percent of affected patients, PG is associated with systemic disease including inflammatory bowel disease, arthritis, and hematologic malignancies. Diagnosis of PG is based on clinical presentation, histopathology and on the exclusion of other diseases that can produce clinically similar lesions, e.g. infection, vasculitis, malignancy, collagen vascular diseases, diabetes, and trauma. Four variants of PG have been described: ulcerative, pustular, bullous, and vegetative. We report a woman with renal failure who developed PG in the absence of any obvious triggering trauma in a distinctive unilateral crop just distal to an arteriovenous dialysis shunt.展开更多
文摘Voriconazole, a second-generation triazole, has recently been appro ved by t he Food and Drug Administration (FDA) to treat invasive aspergillosis and refrac tory infections with Scedosporium apiospermum or Fusarium spp. The reported side -effects of voriconazole include visual changes, headaches, elevated hepatic e nzymes, Steven-Johnson syndrome, toxic epidermal necrolysis, chelitis, photose nsitivity, discoid lupus erythematosus and anaphylactoid infusion reactions. Pse udoporphyria was first described in association with nalidixic acid. It has the same clinical and histologic features as porphyria cutanea tarda (PCT) but is di stinguished by normal porphyrin levels in the serum, urine and stool. We present the case of a patient who developed pseudoporphyria after receiving treatment w ith voriconazole.
文摘Pyoderma gangrenosum (PG) is an uncommon cutaneous disease of unknown etiology. In 50 percent of affected patients, PG is associated with systemic disease including inflammatory bowel disease, arthritis, and hematologic malignancies. Diagnosis of PG is based on clinical presentation, histopathology and on the exclusion of other diseases that can produce clinically similar lesions, e.g. infection, vasculitis, malignancy, collagen vascular diseases, diabetes, and trauma. Four variants of PG have been described: ulcerative, pustular, bullous, and vegetative. We report a woman with renal failure who developed PG in the absence of any obvious triggering trauma in a distinctive unilateral crop just distal to an arteriovenous dialysis shunt.
